Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD33 FPBMC in MRD+ AML or MDS
NCT07270978Phase 1Recruiting
- Sponsor
- University of Virginia
- Start
- Mar 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN), sponsored by University of Virginia. Primary endpoint: Dose Limiting Toxicities. Started Mar 2026; status: recruiting.
02
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT07270978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07270978.